If you would like to learn more about future focusIR related events and roundtables, please submit your details here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksImperial Innovations Group Regulatory News (IVO)

  • There is currently no data for IVO

Form 8 (DD) - Touchstone Innovations Plc.

24 May 2017 11:17

FORM 8 (DD)

PUBLIC DEALING DISCLOSURE BY A PARTY TO AN OFFER OR PERSON ACTING IN CONCERT (INCLUDING DEALINGS FOR THE ACCOUNT OF DISCRETIONARY INVESTMENT CLIENTS)

Rules 8.1, 8.2 and 8.4 of the Takeover Code (the “Code”)

1. KEY INFORMATION

(a) Full name of discloser: Invesco Limited
(b) Owner or controller of interests and short positions disclosed, if different from 1(a):

The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named.

(c) Name of offeror/offeree in relation to whose relevant securities this form relates:

Use a separate form for each offeror/offeree

Touchstone Innovations Plc.
(d) Status of person making the disclosure:

e.g. offeror, offeree, person acting in concert with the offeror/offeree (specify name of offeror/offeree)

Acting in concert with both Touchstone Innovations Plc. and with the IP Group Plc.
(e) Date dealing undertaken: 23.05.2017
(f) In addition to the company in 1(c) above, is the discloser making disclosures in respect of any other party to the offer?

If it is a cash offer or possible cash offer, state “N/A”

YES :

IP Group Plc.

2. POSITIONS OF THE PERSON MAKING THE DISCLOSURE

If there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2(a) or (b) (as appropriate) for each additional class of relevant security.

(a) Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates following the dealing

Class of relevant security: 3 1/33p ordinary

GB00B170L953

Interests Short positions
Number % Number %
(1) Relevant securities owned and/or controlled: 62,898,455 39.01
(2) Cash-settled derivatives:
(3) Stock-settled derivatives (including options) and agreements to purchase/sell:

TOTAL:

62,898,455 39.01

All interests and all short positions should be disclosed.

Details of any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions).

Details of any securities borrowing and lending positions or financial collateral arrangements should be disclosed on a Supplemental Form 8 (SBL).

(b) Rights to subscribe for new securities (including directors’ and other employee options)

Class of relevant security in relation to which subscription right exists:
Details, including nature of the rights concerned and relevant percentages:

3. DEALINGS BY THE PERSON MAKING THE DISCLOSURE

Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 3(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.

The currency of all prices and other monetary amounts should be stated.

(a) Purchases and sales

(i) Party to an offer or person acting in concert (except for a principal trader in the same group as a connected adviser)

Class of relevant security Purchase/sale Number of securities Price per unit

(ii) Principal trader where the sole reason for the connection is that the principal trader is in the same group as a connected adviser

Class of relevant security Purchases/ sales Total number of securities Highest price per unit paid/received Lowest price per unit paid/received

(b) Cash-settled derivative transactions

Class of relevant security Product description

e.g. CFD

Nature of dealing

e.g. opening/closing a long/short position, increasing/reducing a long/short position

Number of reference securities Price per unit

(c) Stock-settled derivative transactions (including options)

(i) Writing, selling, purchasing or varying

Class of relevant security Product description e.g. call option Writing, purchasing, selling, varying etc. Number of securities to which option relates Exercise price per unit Type

e.g. American, European etc.

Expiry date Option money paid/ received per unit

(ii) Exercise

Class of relevant security Product description

e.g. call option

Exercising/ exercised against Number of securities Exercise price per unit

(d) Other dealings (including subscribing for new securities)

Class of relevant security Nature of dealing

e.g. subscription, conversion

Details Price per unit (if applicable)

4. OTHER INFORMATION

(a) Indemnity and other dealing arrangements

Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the party to the offer or person acting in concert making the disclosure and any other person:

Irrevocable commitments and letters of intent should not be included. If there are no such agreements, arrangements or understandings, state “none”

None

(b) Agreements, arrangements or understandings relating to options or derivatives

Details of any agreement, arrangement or understanding, formal or informal, between the party to the offer or person acting in concert making the disclosure and any other person relating to:

(i) the voting rights of any relevant securities under any option; or

(ii) the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced:

If there are no such agreements, arrangements or understandings, state “none”

None

(c) Attachments

Are any Supplemental Forms attached?

Supplemental Form 8 (Open Positions) NO
Supplemental Form 8 (SBL) NO
Date of disclosure: 24 May 2017
Contact name: Philippa Holmes
Telephone number: 01491 417 447

Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service.

The Panel’s Market Surveillance Unit is available for consultation in relation to the Code’s dealing disclosure requirements on +44 (0)20 7638 0129.

The Code can be viewed on the Panel’s website at www.thetakeoverpanel.org.uk.

View source version on businesswire.com: http://www.businesswire.com/news/home/20170524005542/en/

Copyright Business Wire 2017

Date   Source Headline
24th Apr 200912:06 pmPRNHolding(s) in Company
16th Apr 20097:00 amPRNNotice of Half Year Results
8th Apr 20096:21 pmPRNCompletion of Investment
2nd Apr 200910:45 amPRNClarification re. Investment in Portfolio Company
2nd Apr 20097:00 amPRNInvestment in Portfolio Company
24th Mar 20097:00 amRNSPortfolio Company Nexeon Announces New CEO
20th Feb 20097:00 amRNSSeed Funding in Three New Companies
11th Feb 20097:00 amRNSInvestment in Nexeon Ltd
4th Feb 20096:24 pmPRNHolding(s) in Company
29th Jan 20097:00 amRNSNew Portfolio Company Formation
23rd Jan 200910:49 amRNSNovacem wins rushlight award
20th Jan 20097:00 amRNSHolding(s) in Company
20th Jan 20097:00 amPRNTransfer of shares to Imperial College
7th Jan 20094:18 pmPRNHolding in Company
18th Dec 200812:27 pmPRNPortfolio Company Trade Sale
15th Dec 20083:20 pmPRNResult of AGM
17th Nov 20081:20 pmPRNNotice of AGM
14th Oct 20087:00 amPRNFinal Results
17th Sep 20089:30 amRNSSenior Appointments
11th Sep 20081:27 pmPRNPortfolio Company's Clinical Study Results
15th Aug 20087:00 amRNSPortfolio Companies Receive I
14th Aug 20084:35 pmPRNFormation of subsidiary authorised by FSA
10th Jul 20087:00 amPRNAppointment of non-executive director
2nd Jul 20087:00 amRNSAnnouncement re Recyclatech
23rd Jun 20087:00 amPRNInvestment in OSspray Limited
30th May 20089:00 amRNSInvestment in Evince
30th Apr 20087:00 amPRNHalf-yearly Report
22nd Apr 20083:28 pmPRNNotice of Results
14th Apr 20087:01 amRNSInvestment in Spiral Gateway
13th Mar 200811:53 amRNSTherapeutics portfolio update
21st Feb 20082:35 pmPRNDirectorate Change
20th Feb 200810:51 amRNSDirector/PDMR Shareholding
29th Jan 20087:00 amPRNInvestment in Circassia
21st Jan 200812:26 pmRNSi2india agreement with CCI
14th Jan 200810:30 amRNSBiosciences Deals
12th Dec 20073:04 pmRNSResult of AGM
11th Dec 200711:18 amRNSProof of Concept Programme
29th Nov 20074:00 pmRNSHolding(s) in Company
29th Nov 20073:59 pmRNSHolding(s) in Company
27th Nov 20072:04 pmRNSHolding(s) in Company
22nd Nov 20072:53 pmRNSTotal Voting Rights
22nd Nov 20078:00 amRNSFunding raised for i2india
22nd Nov 20078:00 amRNSAdmission of Shares on AIM
21st Nov 200712:11 pmRNSResult of EGM
14th Nov 200711:25 amRNSHolding(s) in Company
9th Nov 20073:56 pmPRNAnnual Report and Accounts
9th Nov 20079:00 amRNSEPS Licensing Deal
8th Nov 200711:55 amRNSHolding(s) in Company
30th Oct 20072:19 pmPRNCirc re GBP30m Placing
26th Oct 20071:35 pmPRNGBP30m placing successful

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.